title: Should hepatitis B vaccine be used for infants?
abstract: Chronic hepatitis B virus infection causes nearly all the deaths from this virus. As the initial infection occurs without symptoms and decades prior to the onset of cirrhosis and liver cancer, these consequences are rarely recognized as being caused by the virus. Consequently, its public health importance is under-recognized. Safe and effective vaccines have now been available for over 20 years. Concerns have been raised regarding the mercury preservative in vaccines leading to potential toxicity. But the evidence to date does not support any association of hepatitis B vaccine with serious adverse consequences. Protecting infants through immunization is the most effective control strategy. By 2005, over 80% of countries had implemented routine infant immunization. In countries with relatively low rates of hepatitis B virus infection, some have argued to defer immunization until later life. However, these arguments focus on the more visible acute infection. The possible future cost from a single infant infection argues for universal infant hepatitis B immunization--given the very high costs of treating its consequences (e.g., liver transplant) and the very low price of the vaccine.
authors.affiliation: Child Survival and Immunization Unit, Health Section, Programme Division, United Nations Children's Fund (UNICEF), 3 UN Plaza, New York, NY 10017, USA. omansoor@unicef.org
authors.forename: Osman David
authors.initials: OD
authors.lastname: Mansoor
authors.forename: Peter
authors.initials: P
authors.lastname: Salama
mesh_terms: D000367:Age Factors; D014943:Global Health; D017325:Hepatitis B Vaccines / Q000191:economics / Q000627:therapeutic use*; D019694:Hepatitis B, Chronic / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007223:Infant
chemical_list: D017325:Hepatitis B Vaccines